Sevan Multi-Site Solutions Attracts $17.5 Million Investment to Support Continued Growth
10.12.2019 17:00:00 EET | Business Wire | Press release
Sevan Multi-Site Solutions, Inc. (Sevan), a global leader in data analytics, surveys, design, program management and construction services, today announced they have closed a $17.5 million Series A funding round led by ABS Capital Partners, a leading late-stage growth company investor. The funding will be used to expand business offerings, develop new technology and strengthen the company to ensure continued growth and scalability.
“In just over eight years, Sevan has established our reputation as a go-to multi-site program management firm and industry expert,” said Jim Evans, President and CEO of Sevan. “ABS Capital will be a terrific partner in our journey ahead. Their experienced people, culture and deep understanding of technology investments will accelerate our growth. We are delighted to continue to deliver excellence to great clients, and together we will all grow!”
Founded in 2011, Sevan helps clients develop, refresh and update their portfolio of sites. Large public competitors are not typically focused on the multi-site market, and smaller companies are unable to compete with the breadth and quality of services Sevan provides.
There is an increased need to routinely renovate and manage facility operations across broad geographies. Global organizations are devoting more time and capital to maintain and improve existing sites rather than build new ones. Rebrands, new product introductions, joint ventures creating a store within a store and new technology enabling self-service automation are all current drivers of renovation programs.
As a result of the minority investment by ABS Capital Partners, Managing General Partner Phil Clough will join the Sevan board of directors.
“We were impressed by Sevan’s national presence, strong reputation, comprehensive suite of services and technology enablement,” Clough said. “ABS Capital, having successfully invested in a significant number of business services companies over the years, recognizes Sevan’s strong growth as a key indicator of future success.”
This is the first round of institutional capital raised by Sevan. Current customers consist of more than 40 leading corporations across thousands of locations and include McDonald’s, Walgreens, Chipotle, BP, Starbucks, 7-Eleven, DaVita, HCA Healthcare and Walmart.
In 2019, Sevan ranked #713 on the Inc. 5000 list of the nation’s fastest-growing private companies. In October 2018, Sevan was named one of the 100 Best Medium Workplaces by Great Place to Work® and FORTUNE, ranking #29 on the list. Sevan has been recognized as an Employee-Rated Great Place to Work for six consecutive years.
Sevan is a 500-person project management firm headquartered in Downers Grove, Illinois, with an international office in London.
About Sevan
Sevan Multi-Site Solutions, Inc. (Sevan)’s vision is to be the best in the world at delivering data analytics, virtual tours, surveys, design, program management and construction services to organizations with multiple sites. Sevan has a passion for sustaining people, the environment and its clients’ businesses. Sevan helps iconic global brands—including 7-Eleven, AAFES, Albertsons, BP, Bento Box, Chipotle, DaVita, HCA Healthcare, Hallmark, Kroger, McDonald’s, Marathon, Office Depot, Starbucks, Sunoco, Walgreens Boots Alliance and Walmart. Sevan rolls out multi-site initiatives efficiently, predictably and transparently. Applying breakthrough technology solutions, Sevan optimizes new builds, rebuilds, remodels and renovations. The company’s expertise spans numerous market sectors including banking, fuel and convenience store, government, restaurant, grocery, retail, healthcare, housing and hospitality industries. For more information, visit www.sevansolutions.com .
About ABS Capital Partners
For nearly 30 years, ABS Capital has been investing in later-stage growth companies, helping CEOs capitalize on new opportunities and navigate unforeseen obstacles – while never losing sight of the ultimate goal of achieving lasting excellence. Our partners have decades of experience as C-level executives, investment bankers, and investors in the industries in which we invest: business and tech-enabled services and health care. This combination of experience and expertise means we have a laser-focus on the specific needs growth companies face as they look to get to the next level. By helping to transform over 125 companies through their most important stage of development, ABS continues to help unleash the potential for lasting growth. ABS Capital Partners. Here, we grow. For more information, visit www.abscapital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005386/en/
Contact information
Hafsa Mahmood
Manager, Marketing & Communications
Phone: 312.285.0590
Email:
hafsa.mahmood@sevansolutions.com
Website:
www.sevansolutions.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
